Introduction
Lichen planus is an inflammatory mucocutaneous condition. It typically persists for 1 to 2 years, may follow a chronic relapsing course over many years 1,2 . The prevalence of lichen planus is <1% (0.14-0.80%) worldwide 3,4,5 . Relapse of disease occurs in 15 percent to 20 percent of cases and tends to occur in the same area as the initial episode 6 . The primary lesions of lichen planus are characteristic, almost pathognomonic, small, violaceous, flat-topped, polygonal papule. On the surface gray or white puncta or streaks (Wickham striae) cross the lesions. Koebner phenomenon occurs in lichen planus. Pruritus is often prominent in lichen planus 7, 8 . There is a predilection for the flexor wrists, trunk, medial thighs, shins, dorsal hands and glans penis. Nail changes are present in approximately 5-10% and pterygium formation is characteristic 1, 9 . Lichen planus may be a cause of twenty nail dystrophy. Association of lichen planus with syphilis, Herpes Simplex Virus-2 (HSV- 
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EFFICACY OF LOW DOSE LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF CUTANEOUS LICHEN PLANUS.
Low molecular weight heparin in low doses has lymphoid antiproliferative and immunomodulatory properties 11 . Evidence suggests that lichen planus is a T-cell mediated skin disorder. The dermal infiltrate consists largely of T-cells that attach to keratinocytes. This lymphocyte-keratinocyte apposition is believed to lead to the destruction of the epidermis. Administration of low dose low molecular weight heparin (devoid of anticoagulant activity) inhibits T-lymphocyte heparanase activity, which is crucial in T cell migration to target tissues in lichen planus 12 . In Bangladesh, low molecular weight heparin has recently been used to treat lichen planus. Unfortunately there are few studies taken regarding this drug over Bangladeshi people. The present study was designed to assess the effectiveness of low dose low molecular weight heparin in the treatment of cutaneous lichen planus.
Materials and Methods
An interventional study was carried out for a period from July 2009 to June 2010, in the department of Dermatology and Venereology, Combined Military Hospital (CMH), Dhaka. Purposive type non-probability sampling technique was followed in this study. Data were collected from the patients by face to face interview and also from clinical records. Questionnaire was developed for collection of relevant information. Patients suffering from lichen planus were selected as study population. During the data collection period, 37 patients of cutaneous lichen planus were assigned purposively, considering inclusion and exclusion criteria for patient selection. At first the patients of cutaneous lichen planus were identified. Then clinical conditions of the patients were recorded and skin biopsies were done for histopathological examination. After that verbal and written consent were taken from the selected patients; they were interviewed by asking questions. Present clinical conditions were recorded, along with follow up in subsequent visits of selected patients. The questionnaire included selected parameters related to clinical characteristics, the grading of complaints, the clinical findings before and after treatment and the level of improvement after application of drug. After collection, all the data were cleaned by checking consistency and then were edited and analyzed by software SPSS-12.0 (Statistical Package for Social Science) and were presented according to objectives and variables of the study.
Inclusion criteria
Procedure of Treatment:
All patients of cutaneous lichen planus were treated with 3 mg/ml low molecular weight heparin (enoxaparin), subcutaneously once in a week for duration of 6 weeks. Additional therapies were restricted. First follow-up was done after 4 weeks and second follow up was done after 8 weeks of administration of last dose of medication.
Clinical Assessment: Skin involvement before and after therapy was assessed by a clinical score. Briefly the method consists of determination of different grades of papules, scaly lesions and pigmentation: 0 = normal, 1 = mild, 2 = moderate and 3 = severe for all. Total clinical score of each single patient was determined by addition of the scores. Response study was recorded as: Excellent > 75% improvement, Good 50-75% clearing, Fair 25-50% clearing and Poor <25% clearing.
Results
This study is an interventional type of study, conducted on thirty-seven patients with a view to assess the efficacy of low dose low molecular weight heparin for the treatment of cutaneous lichen planus.
Table-I shows that the mean age of the patients was 36 ± 6.6 years and their age ranged from 20 to 50 years. Among the 37 patients, highest percentage of patients, 21 (56.8%) were in between the 30 to 40 years of age, followed by 10 (27%) who were 40 to 50 years of age and 6 (16.2%) were in between 20 to 30 years of age. Table- IV, level of improvement was observed on the 1st follow up visit at the end of 4 weeks. Response was fair in 10 (38.46%) cases and poor in 16 (61.54%) cases. Marked improvement observed on the 2nd follow up visit at the end of 8 weeks. Response was good in 23 (88.46%) cases, fair in 2 (7.69%) cases and poor in 1 (3.85%) cases. Statistical test was done and found significant (p<05).
Table-IV: Distribution of response of treatment at different weeks (n=37).
It was seen in the study that 29 (78.4%) patients had no side effects and 8 (21.6%) had side effects of drug, shown in Fig-2 . Among the patients having side effects, 5(62.50%) suffered from local irritation, 2(25.0%) from bruises and 1(12.5%) patient suffered from headache, shown in Fig-3 .
Discussion
A total of thirty seven patients were studied. The mean age of the patients was 36±6.6 years and their age ranged from 20 to 50 years. Among the patients, highest percentage of patients, 21(56.8%) were in between 30 to 40 years of age, followed by 10(27%) were 40 to 50 years old and 6 (16.2%) were in between the 20-30 years of age, similar to the study finding of Kanwar It was seen that 29(78.4%) had no side effect and 8(21.6%) had side effects of drugs, not similar to the study finding of Akdeniz et al, where twenty four patients were treated by low molecular weight heparin and complete remission was observed without any side effect 15 . Similar study finding was also observed by Pacheco et al when seven patients of cutaneous lichen planus were treated with low-molecular weight heparin where marked improvement was seen without any side effect 17 .
Conclusion
The study revealed that improvement was good in three-fourth cases. So, it can be concluded that low dose low molecular weight heparin has remarkable efficacy profile as treatment option for cutaneous lichen planus. As low molecular weight heparin is still expensive, further studies to evaluate costeffectiveness may be performed. This was an open and uncontrolled study on a limited number of cases. Further blinded, randomized, placebo-controlled studies are needed to investigate the effectiveness of therapy.
